Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Evaluation of Virucidal Activity of Residual Quaternary Ammonium-treated Surfaces on SARS-CoV-2

11 May 2021, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

A commercially available and EPA/PMRA registered quaternary ammonium antimicrobial formulation was applied to stainless steel carrier disks and sent to two virology research institutes to independently determine whether samples treated with SiQAC-C18 antimicrobial material could deactivate deposited SARS-CoV-2 virions on contaminated surfaces. The results independently support a sustained antiviral effect imparted from these treated surfaces by both SARS-CoV-2 virion destruction and degradation of viral RNA. These preliminary results indicate the SiQAC-18 treated surfaces could play an important role in mitigating the communicability and fomite transmission of SARS-CoV-2.

Keywords

Self-disinfecting Surface
Biocidal Treatment
Fomite Spread
SARS-CoV-2
Coronavirus

Supplementary materials

Title
Description
Actions
Title
S1 Rega Institute Evaluation of ViaClean Disinfectants against SARS-CoV-2 in vitro
Description
Actions
Title
S2 C. REPORT 1 DOHERTY 110620 TEST B ViaClean EPA Report
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

May 11, 2021 Version 1

Metrics

1,439
571
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.14555796.v1
D O I: 10.26434/chemrxiv.14555796.v1 [opens in a new tab]

Funding

No Funding to declare

Author’s competing interest statement

The virology research in this study was funded by ViaClean Technologies Inc. who supported testing for the SARS-CoV-2 trials in Australia and Belgium. The results of these trials were shared with Foucher and Caschera. Foucher and Caschera received no compensation from any party for their efforts in preparing and submitting a manuscript.

Share